Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer

Matsuda, Hiroyuki; Ogawa, Toru; Sadatsuki, Yasunari et al.

Respiratory Investigation, 2023, 61(1), 61-73

Permalink : https://hdl.handle.net/2115/88929

このアイテムのアクセス数:287件（2026-10-08 20:46 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
https://doi.org/10.1016/j.resinv.2022.10.002     22

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/88929
タイトル
Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer
著者
Matsuda, Hiroyuki ; Ogawa, Toru ; Sadatsuki, Yasunari ; Tsujino, Toshiaki ; Wada, Shingo ; Kim, Seok-Won ; Hatanaka, Yutaka
著者名
Matsuda, Hiroyuki
著者名
Ogawa, Toru
著者名
Sadatsuki, Yasunari
著者名
Tsujino, Toshiaki
著者名
Wada, Shingo
著者名
Kim, Seok-Won
e-Rad_Researcher
30589924
著者名
Hatanaka, Yutaka
言語
英語
キーワード
Non-small-cell lung cancer
Sequential single-gene test
Next generation sequencing
Budget impact
Turnaround times
発行日
2023-01
出版者
Elsevier
収録物名
Respiratory Investigation
巻(号)
61(1)
ページ
61-73
抄録
Background: Identification of genomic alterations (e.g., EGFR, ALK, ROS1, BRAF, NTRK, and MET) is essential for initiating targeted therapy in patients with advanced non-small-cell lung cancer (aNSCLC). This study estimated the budget impact of using the sequential single-gene (SSG) test, which tests for each mutation one at a time, versus next-generation sequencing (NGS), which tests for all mutations at the same time, among newly diagnosed patients with aNSCLC from a Japanese healthcare payer's perspective. Methods: A budget impact model (BIM) was used to determine the expected budget impact associated with NGS for newly diagnosed aNSCLC in Japan over a 3-year period. The BIM compared the total costs (biopsy, testing, and treatment) and average turnaround time of future NGS and current NGS versus SSG testing. Results: The adoption of current NGS over SSG testing had a budget impact of-0.24%, but adoption of future NGS over SSG testing had a budget impact of thorn 4.33% across a 3-year time horizon on the Japanese budget for aNSCLC treatment. The adoption of current or future NGS over SSG testing would shorten the average turnaround time for testing. Conclusions: The adoption of current NGS over SSG testing would slightly decrease the yearly costs. However, the adoption of future or current NGS over SSG testing would shorten the average turnaround time, enabling faster identification of genomic alterations and earlier initiation of treatment for aNSCLC patients in Japan. (c) 2022 The Authors. Published by Elsevier B.V. on behalf of The Japanese Respiratory So-ciety. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
PISSN
2212-5345
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.1016/j.resinv.2022.10.002